keyboard_arrow_up

Pipeline of Cystic Fibrosis Market Review H2 2015

RnRMarketResearch.com adds Cystic Fibrosis Pipeline 2015 Research to its database, providing in-depth, high quality, transparent and market-driven, expert analysis of disease. This report provides comprehensive information on the therapeutic development for Cystic Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cystic Fibrosis and special features on late-stage and discontinued projects.

Complete research on pipeline assessment review of Cystic Fibrosis with 98 market data tables and 17 figures, spread across 368 pages is available at http://www.rnrmarketresearch.com/cystic-fibrosis-pipeline-review-h2-2015-market-report.html .

Scope of this research:

·         The report provides a snapshot of the global therapeutic landscape of Cystic Fibrosis

·         The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

·         The report reviews key players involved in the therapeutics development for Cystic Fibrosis and enlists all their major and minor projects

·         The report summarizes all the dormant and discontinued pipeline projects

·         A review of the Cystic Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

·         Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

·         A detailed assessment of monotherapy and combination therapy pipeline projects

·         Coverage of the Cystic Fibrosis pipeline on the basis of target, MoA, route of administration and molecule type

·         Latest news and deals relating related to pipeline products

Inquire before buying this research @ http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=459956 .

Reasons to buy

·         Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

·         Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

·         Develop strategic initiatives by understanding the focus areas of leading companies

·         Identify and understand important and diverse types of therapeutics under development for Cystic Fibrosis

·         Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

·         Devise corrective measures for pipeline projects by understanding Cystic Fibrosis pipeline depth and focus of Indication therapeutics

·         Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

·         Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Company Profiles: Actelion Ltd, Akari Therapeutics, Plc, Alaxia SAS, AlgiPharma AS, AmpliPhi Biosciences Corporation, Arcturus Therapeutics, Inc, Aridis Pharmaceuticals LLC, Bayer AG, Boehringer Ingelheim GmbH, Carolus Therapeutics, Inc., Celtaxsys, Inc., Chiesi Farmaceutici SpA, Cilian AG, Concert Pharmaceuticals, Inc., Corbus pharmaceuticals, Inc., Cyclacel Pharmaceuticals, Inc., DiscoveryBiomed, Inc., Errant Gene Therapeutics, LLC, Galapagos NV, GlaxoSmithKline Plc, Grifols, S.A., Grupo Praxis Pharmaceutical SA, Horizon Pharma Plc, Insmed Incorporated, Invion Limited, JHL Biotech, Inc., Kamada Ltd., La Jolla Pharmaceutical Company, Lamellar Biomedical Ltd, Laurent Pharmaceuticals Inc., Merck & Co., Inc., Microbion Corporation, Mucokinetica Ltd., NanoBio Corporation, Nivalis Therapeutics, Inc., Nostrum Pharmaceuticals, LLC, Novabiotics Limited, Novartis AG, OSE Pharma SA, Parion Sciences, Inc., Pfizer Inc., Pharmaxis Limited, PhaseBio Pharmaceuticals, Inc., Polyphor Ltd., Progenra, Inc., ProQR Therapeutics N.V., Protalix BioTherapeutics, Inc., Proteostasis Therapeutics, Inc., PTC Therapeutics, Inc., Pulmatrix, Inc., ReveraGen BioPharma, Inc., Savara Inc., Serendex Pharmaceuticals A/S, Shionogi & Co., Ltd., Shire Plc, Synovo GmbH, TGV-Laboratories, The International Biotechnology Center (IBC) Generium, Verona Pharma Plc, Vertex Pharmaceuticals Incorporated, Xenetic Biosciences plc and Zambon Company S.p.A.